NASDAQ:XGN Exagen (XGN) Stock Forecast, Price & News $2.42 -0.03 (-1.22%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$2.42▼$2.5450-Day Range$2.24▼$2.7752-Week Range$2.04▼$4.20Volume5,033 shsAverage Volume11,215 shsMarket Capitalization$40.80 millionP/E RatioN/ADividend YieldN/APrice Target$6.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Exagen MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside158.3% Upside$6.25 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.59Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.62) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector167th out of 971 stocksMedical Laboratories Industry7th out of 25 stocks 3.5 Analyst's Opinion Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Exagen has a forecasted upside of 158.3% from its current price of $2.42.Amount of Analyst CoverageExagen has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.15% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently increased by 27.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Exagen is -1.29. Previous Next 2.0 News and Social Media Coverage News SentimentExagen has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Exagen this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for XGN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have not sold or bought any company stock.Percentage Held by Insiders36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.85% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($1.62) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exagen (NASDAQ:XGN) StockExagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Read More XGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XGN Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comExagen Inc. (NASDAQ:XGN) Short Interest Up 27.8% in SeptemberSeptember 28, 2023 | finance.yahoo.comExagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual MeetingOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 27, 2023 | americanbankingnews.comExagen (NASDAQ:XGN) Stock Rating Reaffirmed by Cantor FitzgeraldSeptember 12, 2023 | finance.yahoo.comExagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceAugust 9, 2023 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call TranscriptAugust 7, 2023 | msn.comExagen beats Q2 top and bottom line estimates; initiates Q3 outlookAugust 7, 2023 | finance.yahoo.comExagen Inc. Reports Strong Second Quarter 2023 ResultsOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 4, 2023 | benzinga.comExagen's Earnings OutlookJuly 26, 2023 | finance.yahoo.comExagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceJuly 25, 2023 | finance.yahoo.comExagen to Announce Second Quarter 2023 Financial Results on August 7, 2023July 24, 2023 | finance.yahoo.comExagen Inc. Appoints Paul Kim to Board of DirectorsJuly 24, 2023 | finance.yahoo.comThis Exagen Insider Increased Their Holding In The Last YearJune 13, 2023 | finance.yahoo.comExagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For ExcitementMay 30, 2023 | finance.yahoo.comExagen Inc. to Participate in the William Blair 43rd Annual Growth Stock ConferenceMay 17, 2023 | finance.yahoo.comExagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three yearsMay 16, 2023 | msn.comCantor Fitzgerald Reiterates Exagen (XGN) Overweight RecommendationMay 16, 2023 | markets.businessinsider.comCantor Fitzgerald Reaffirms Their Buy Rating on Exagen (XGN)May 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Exagen (XGN)May 15, 2023 | finance.yahoo.comExagen Inc. Reports First Quarter 2023 ResultsMay 1, 2023 | finance.yahoo.comExagen Announces Campaign for Lupus Awareness MonthApril 24, 2023 | finance.yahoo.comExagen to Announce First Quarter 2023 Financial Results on May 15, 2023March 24, 2023 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call TranscriptMarch 22, 2023 | finance.yahoo.comExagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2023 | finance.yahoo.comExagen Inc. Reports Fourth Quarter and Full Year 2022 ResultsMarch 20, 2023 | markets.businessinsider.comHere's what Wall Street expects from Exagen's earningsSee More Headlines Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address XGN Company Calendar Last Earnings8/07/2023Today10/01/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XGN CUSIPN/A CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees199Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.25 High Stock Price Forecast$7.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+158.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,390,000.00 Net Margins-66.41% Pretax Margin-66.94% Return on Equity-74.00% Return on Assets-37.20% Debt Debt-to-Equity Ratio0.60 Current Ratio5.96 Quick Ratio5.96 Sales & Book Value Annual Sales$45.56 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.93Miscellaneous Outstanding Shares16,860,000Free Float10,655,000Market Cap$40.80 million OptionableNot Optionable Beta1.17 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Tina S. Nova Ph.D. (Age 69)Exec. Chairman of Board Comp: $65kMr. John Aballi (Age 38)CEO, Pres & Director Comp: $558.84kMr. Kamal Adawi M.S. (Age 44)MBA, CFO & Corp. Sec. Comp: $483.28kMr. Mark Hazeltine (Age 49)Chief Bus. Officer Comp: $483.28kRyan DouglasInvestors Relations OfficerMr. John Wegener (Age 54)Sr. VP of Sales and Marketing Dr. Andrew L. Concoff FACRM.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardDr. Michael I. Nerenberg M.D. (Age 68)Chief Medical Officer More ExecutivesKey CompetitorsTriSalus Life SciencesNASDAQ:TLSICentogeneNASDAQ:CNTGDermTechNASDAQ:DMTKPsychemedicsNASDAQ:PMDPersonalisNASDAQ:PSNLView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCBought 12,278 shares on 8/16/2023Ownership: 6.224%Citadel Advisors LLCSold 7,200 shares on 8/15/2023Ownership: 0.000%Silvercrest Asset Management Group LLCBought 44,518 shares on 8/14/2023Ownership: 3.245%Stonepine Capital Management LLCBought 12,278 shares on 8/11/2023Ownership: 6.224%Cowen AND Company LLCSold 101,176 shares on 8/7/2023Ownership: 4.999%View All Insider TransactionsView All Institutional Transactions XGN Stock - Frequently Asked Questions Should I buy or sell Exagen stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks. What is Exagen's stock price forecast for 2023? 3 equities research analysts have issued 12 month price targets for Exagen's stock. Their XGN share price forecasts range from $5.00 to $7.00. On average, they expect the company's stock price to reach $6.25 in the next year. This suggests a possible upside of 158.3% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts. How have XGN shares performed in 2023? Exagen's stock was trading at $2.40 at the start of the year. Since then, XGN stock has increased by 0.8% and is now trading at $2.42. View the best growth stocks for 2023 here. Are investors shorting Exagen? Exagen saw a increase in short interest in September. As of September 15th, there was short interest totaling 12,400 shares, an increase of 27.8% from the August 31st total of 9,700 shares. Based on an average trading volume of 15,100 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.2% of the company's stock are sold short. View Exagen's Short Interest. When is Exagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our XGN earnings forecast. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) issued its earnings results on Monday, August, 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. The business had revenue of $14.14 million for the quarter, compared to the consensus estimate of $10.97 million. Exagen had a negative trailing twelve-month return on equity of 74.00% and a negative net margin of 66.41%. What guidance has Exagen issued on next quarter's earnings? Exagen updated its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.00 million-$10.50 million, compared to the consensus revenue estimate of $11.76 million. What is Ron Rocca's approval rating as Exagen's CEO? 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees. When did Exagen IPO? (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO. What is Exagen's stock symbol? Exagen trades on the NASDAQ under the ticker symbol "XGN." How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exagen's stock price today? One share of XGN stock can currently be purchased for approximately $2.42. How much money does Exagen make? Exagen (NASDAQ:XGN) has a market capitalization of $40.80 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. How many employees does Exagen have? The company employs 199 workers across the globe. How can I contact Exagen? Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via phone at 760-560-1501 or via email at ir@exagen.com. This page (NASDAQ:XGN) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.